Skip to content
Providing the evidence base to reduce harmful AOD use in
Aboriginal and Torres Strait Islander communities
This document is intended to provide a broad policy context and a framework for medication-assisted treatment of opioid dependence.
It provides clinical guidelines on approaches involving the use of methadone, buprenorphine or naltrexone for the treatment of opioid dependence. It aims to provide guidance in the selection and management of patients seeking pharmacotherapies for opioid dependence, and to support the provision to patients of accurate information about methadone, buprenorphine and naltrexone.
This document updates and replaces four previously separate documents:
Abstract adapted from National Drug Strategy
The National drug strategy 2010-2015 is a framework for action on alcohol, tobacco and other drugs.
The aim of the National drug strategy 2010-2015 is to build safe and healthy communities by minimising alcohol, tobacco and other drug-related health, social and economic harms among individuals, families and communities.
The National drug strategy 2010-2015 is divided into three parts:
Abstract adapted from the National drug strategy